Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data …
2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
Wuhan to world: the COVID-19 pandemic
COVID-19 is a Severe Acute Respiratory Syndrome (SARS), caused by SARS-CoV-2, a
novel virus which belongs to the family Coronaviridae. It was first reported in December …
novel virus which belongs to the family Coronaviridae. It was first reported in December …
The impact of pre-existing comorbidities and therapeutic interventions on COVID-19
LA Callender, M Curran, SM Bates… - Frontiers in …, 2020 - frontiersin.org
Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals
with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of …
with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of …
The European guideline on management of major bleeding and coagulopathy following trauma
R Rossaint, B Bouillon, V Cerny, TJ Coats, J Duranteau… - Critical care, 2016 - Springer
Background Severe trauma continues to represent a global public health issue and mortality
and morbidity in trauma patients remains substantial. A number of initiatives have aimed to …
and morbidity in trauma patients remains substantial. A number of initiatives have aimed to …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
SJ Valk, C Kimber, E Dorando, I Monsef… - Cochrane Database …, 2021 - cochranelibrary.com
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are being investigated as potential therapies …
in patients with viral respiratory diseases, and are being investigated as potential therapies …
[HTML][HTML] Haemostatic alterations and management of haemostasis in patients with cirrhosis
T Lisman, SH Caldwell, NM Intagliata - Journal of Hepatology, 2022 - Elsevier
Patients with cirrhosis frequently acquire complex changes in their haemostatic system
including a decreased platelet count and decreased levels of various haemostatic proteins …
including a decreased platelet count and decreased levels of various haemostatic proteins …
COVID-19: therapeutics and their toxicities
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19
pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity …
pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity …
Psychopharmacology of COVID-19
M Bilbul, P Paparone, AM Kim, S Mutalik, CL Ernst - Psychosomatics, 2020 - Elsevier
Background With the rapid, global spread of severe acute respiratory syndrome coronavirus
2, hospitals have become inundated with patients suffering from coronavirus disease 2019 …
2, hospitals have become inundated with patients suffering from coronavirus disease 2019 …
Cryoprecipitate therapy
B Nascimento, LT Goodnough… - British journal of …, 2014 - academic.oup.com
Cryoprecipitate, originally developed as a therapy for patients with antihaemophilic factor
deficiency, or haemophilia A, has been in use for almost 50 yr. However, cryoprecipitate is …
deficiency, or haemophilia A, has been in use for almost 50 yr. However, cryoprecipitate is …